Stu Needleman, Chief Commercial Officer at Piramal Pharma Solutions, discusses the Biosecure Act and other big trends shaking up the industry, including GLP-1s, consolidation in the CDMO sector, and sterile fill-finish. He tells us more about Piramal’s $80-million expansion in Kentucky and how the company is adapting to the changes in the market. Check out the video!
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
March 26, 2025
3 min read
With competition for skilled employees in cell and gene therapy manufacturing high, companies need to ensure they are investing in training and mentorship.
February 13, 2025
4 min read
Why you shouldn’t neglect the importance of blending people, culture, and strategy to foster success in a business.
February 25, 2025
3 min read
How do you design, refine, and optimize novel GLP-1 drugs that could improve patient experiences? With a computer, of course.
January 16, 2025
3 min read
The trends and challenges in oral solid dosage formulations contribute to greater stability for drugs used by patients worldwide.